Dulaglutide Dulaglutide (Trulicity) is administered subcutaneously at a maximum dose of 1.5 mg once weekly, and available on license since 2014 for people with T2D as monotherapy in those who cannot take metformin or as add-on treatment in people using oral agents and/or insulin
Retatrutide is still in late-stage clinical trials and is not yet FDA approved or commercially available
The purine component in NAD + is adenine, which is incorporated from ATP 23
Probiotics Taking a high-quality probiotic supplement might help rebalance gut bacteria and reduce hydrogen sulfide production over time
Last Published 04.01.2026 Effective Date: 04.01.2026 This policy addresses the use of Bkemv (eculizumab-aeeb), Epysqli (eculizumab-aagh), PiaSky (crovalimab-akkz), Soliris (eculizumab), and Ultomiris (ravulizumab-cwvz)
Semaglutide vs Tirzepatide vs Retatrutide Semaglutide (GLP-1): Proven weekly med that curbs appetite and slows gastric emptying to help you feel full on fewer calories